This document is a press release from Cardinal Health announcing their fiscal 2008 results and fiscal 2009 outlook. Some key points:
- Fiscal 2008 revenue increased 5% to $91 billion and GAAP EPS increased 76% to $3.64. Non-GAAP EPS grew 11% to $3.80.
- The company is exploring a potential spin-off of their clinical and medical products businesses into a separate publicly traded company.
- For fiscal 2009, revenue is expected to grow 6-7% while non-GAAP EPS is expected to be between $3.80-$3.95, though investments in R&D and IT may impact near-term growth.
- Challenges in the
- Cardinal Health reported a 5% increase in third quarter revenue to $22.9 billion and GAAP EPS of $1.02, compared to a $0.01 loss in the prior year. Non-GAAP EPS increased 13% to $1.08.
- Revenue growth was driven by the healthcare supply chain medical segment and clinical and medical products sector. However, the supply chain pharmaceutical segment faced challenges including customer disruption and slower market growth.
- The company reaffirmed its fiscal year 2008 non-GAAP EPS guidance range of $3.75 to $3.85.
Cardinal Health reported a 7% increase in second quarter revenue to $23 billion. Diluted earnings per share from continuing operations increased 16% to $0.89. However, Cardinal Health revised its full-year earnings per share guidance downward to a range of $3.75 to $3.85 due to issues affecting its pharmaceutical distribution business, including anti-diversion measures and contract repricings.
Cardinal Health reported second quarter results for fiscal year 2009, with revenue increasing 8% to $25 billion compared to the same period last year. GAAP earnings from continuing operations declined 2% to $319 million, while non-GAAP earnings increased 2% to $335 million. Both the Healthcare Supply Chain Services and Clinical and Medical Products segments saw revenue growth, with Healthcare Supply Chain Services segment profit increasing 6% and Clinical and Medical Products segment profit growing 16%. The company reaffirmed its full-year non-GAAP EPS guidance of $3.50 to $3.60.
- Cardinal Health reported third-quarter results with revenue increasing 8% to nearly $22 billion and a loss of $5 million or $0.01 per share due to a $600 million litigation reserve.
- On a non-GAAP basis, earnings from continuing operations increased 10% to $390 million or 16% to $0.96 per share.
- The company closed the $3.3 billion sale of its PTS business and repurchased $1.4 billion in shares during the quarter.
- Cardinal Health reported first quarter results for fiscal year 2007, with revenue increasing 11% to $21.4 billion and earnings from continuing operations rising 26% to $300 million.
- Key drivers of growth included strong performance in the Healthcare Supply Chain Services-Pharmaceutical segment due to higher generic drug sales and expense controls. The Medical Products Manufacturing segment also had solid results.
- For fiscal year 2007, Cardinal Health reiterated its outlook for non-GAAP diluted EPS from continuing operations to be in the range of $3.50 to $3.70.
- Cardinal Health reported strong second-quarter results for fiscal year 2007, with revenue increasing 13% to $21.8 billion and earnings per share increasing 17% to $0.77.
- All four of Cardinal Health's continuing business segments experienced solid revenue and earnings growth. The company also plans to broaden its specialty pharmaceutical offerings through the acquisition of SpecialtyScripts Pharmacy.
- For the fiscal year, Cardinal Health reiterated its guidance range of $3.25 to $3.40 for non-GAAP diluted earnings per share from continuing operations.
Bruker reported Q2 2017 financial results with revenue increasing 11.6% year-over-year to $414.9 million. Organic revenue growth was 7.6% while acquisitions contributed 5.8% growth. The operating margin expanded 170 basis points to 12.5% of revenues due to revenue growth and 2016 restructuring benefits. Non-GAAP EPS grew 15% to $0.23 per share despite a higher effective tax rate compared to the prior year period. For the full year 2017, Bruker expects revenue to increase 4.5-6.0% and for the non-GAAP operating margin to expand 40-70 basis points.
P&G Delivers Strong Sales and EPS Results Despite Hurricane Impactsfinance3
P&G delivered strong sales and earnings results in the July-September quarter despite impacts from hurricanes. Sales grew 8% to $14.79 billion and earnings per share grew 10% to $0.77, beating analyst estimates. All business segments saw sales and volume growth, led by beauty, health care, and household care. Growth was broad-based across brands, countries, and regions. Developing markets grew volumes in the mid-teens. The results demonstrated the company's ability to deliver consistent growth in both good and challenging times.
- Cardinal Health reported a 5% increase in third quarter revenue to $22.9 billion and GAAP EPS of $1.02, compared to a $0.01 loss in the prior year. Non-GAAP EPS increased 13% to $1.08.
- Revenue growth was driven by the healthcare supply chain medical segment and clinical and medical products sector. However, the supply chain pharmaceutical segment faced challenges including customer disruption and slower market growth.
- The company reaffirmed its fiscal year 2008 non-GAAP EPS guidance range of $3.75 to $3.85.
Cardinal Health reported a 7% increase in second quarter revenue to $23 billion. Diluted earnings per share from continuing operations increased 16% to $0.89. However, Cardinal Health revised its full-year earnings per share guidance downward to a range of $3.75 to $3.85 due to issues affecting its pharmaceutical distribution business, including anti-diversion measures and contract repricings.
Cardinal Health reported second quarter results for fiscal year 2009, with revenue increasing 8% to $25 billion compared to the same period last year. GAAP earnings from continuing operations declined 2% to $319 million, while non-GAAP earnings increased 2% to $335 million. Both the Healthcare Supply Chain Services and Clinical and Medical Products segments saw revenue growth, with Healthcare Supply Chain Services segment profit increasing 6% and Clinical and Medical Products segment profit growing 16%. The company reaffirmed its full-year non-GAAP EPS guidance of $3.50 to $3.60.
- Cardinal Health reported third-quarter results with revenue increasing 8% to nearly $22 billion and a loss of $5 million or $0.01 per share due to a $600 million litigation reserve.
- On a non-GAAP basis, earnings from continuing operations increased 10% to $390 million or 16% to $0.96 per share.
- The company closed the $3.3 billion sale of its PTS business and repurchased $1.4 billion in shares during the quarter.
- Cardinal Health reported first quarter results for fiscal year 2007, with revenue increasing 11% to $21.4 billion and earnings from continuing operations rising 26% to $300 million.
- Key drivers of growth included strong performance in the Healthcare Supply Chain Services-Pharmaceutical segment due to higher generic drug sales and expense controls. The Medical Products Manufacturing segment also had solid results.
- For fiscal year 2007, Cardinal Health reiterated its outlook for non-GAAP diluted EPS from continuing operations to be in the range of $3.50 to $3.70.
- Cardinal Health reported strong second-quarter results for fiscal year 2007, with revenue increasing 13% to $21.8 billion and earnings per share increasing 17% to $0.77.
- All four of Cardinal Health's continuing business segments experienced solid revenue and earnings growth. The company also plans to broaden its specialty pharmaceutical offerings through the acquisition of SpecialtyScripts Pharmacy.
- For the fiscal year, Cardinal Health reiterated its guidance range of $3.25 to $3.40 for non-GAAP diluted earnings per share from continuing operations.
Bruker reported Q2 2017 financial results with revenue increasing 11.6% year-over-year to $414.9 million. Organic revenue growth was 7.6% while acquisitions contributed 5.8% growth. The operating margin expanded 170 basis points to 12.5% of revenues due to revenue growth and 2016 restructuring benefits. Non-GAAP EPS grew 15% to $0.23 per share despite a higher effective tax rate compared to the prior year period. For the full year 2017, Bruker expects revenue to increase 4.5-6.0% and for the non-GAAP operating margin to expand 40-70 basis points.
P&G Delivers Strong Sales and EPS Results Despite Hurricane Impactsfinance3
P&G delivered strong sales and earnings results in the July-September quarter despite impacts from hurricanes. Sales grew 8% to $14.79 billion and earnings per share grew 10% to $0.77, beating analyst estimates. All business segments saw sales and volume growth, led by beauty, health care, and household care. Growth was broad-based across brands, countries, and regions. Developing markets grew volumes in the mid-teens. The results demonstrated the company's ability to deliver consistent growth in both good and challenging times.
J.P. Morgan 33rd Annual Healthcare ConferenceCardinal_Health
This document contains the transcript from George S. Barrett's presentation at the J.P. Morgan Healthcare Conference on January 13, 2015. It discusses Cardinal Health's strategic priorities including growing its specialty pharmaceutical, generic drug sourcing, and international businesses. It also outlines opportunities in health system solutions, alternate sites of care, and the home healthcare market. The presentation notes Cardinal Health's sustained financial performance and future aspirations for metrics like operating margin and earnings growth. It emphasizes the company's focus on key trends in healthcare like increased consumerism, transition to value-based care, and continued innovation.
P&G Delivers Results Above Expectations - Raises Fiscal Year Outlookfinance3
P&G reported financial results for the quarter ending December 2006 that were above expectations. Strong sales growth of P&G and newly acquired Gillette brands drove higher earnings per share despite costs associated with the Gillette acquisition. Net sales increased 27% to $18.34 billion due to a 27% increase in unit volume. Organic sales, excluding acquisitions and divestitures, grew 8%. Earnings per share were $0.72, in line with the prior year despite an estimated $0.06-$0.07 per share dilution from the Gillette acquisition. The company raised its full year earnings outlook based on the strong quarterly results and integration progress of Gillette.
J.P. Morgan 34th Annual Healthcare Conference PresentationCardinal_Health
This document is a presentation from Cardinal Health's Chairman and CEO George Barrett given at the J.P. Morgan Healthcare Conference on January 12, 2016. The presentation provides an overview of Cardinal Health, including key facts about the company, its two business segments and growth drivers, financial highlights and goals, capital deployment, and positioning in the changing healthcare industry. It emphasizes Cardinal Health's focus on serving customers across the care continuum.
- Cardinal Health reported financial results for Q1 FY2016 with revenue increasing 17% year-over-year to $28.1 billion and non-GAAP diluted EPS increasing 38% to $1.38.
- The Pharmaceutical segment saw a 19% revenue increase to $25.1 billion and a 46% increase in segment profit to $657 million due to growth from existing and new customers.
- The Medical segment reported a 2% revenue increase to $2.9 billion but an 11% decline in segment profit to $101 million primarily due to Cardinal Health's Canada business.
- For FY2016, Cardinal Health expects mid-teens revenue growth and non-GAAP diluted EPS between
McKesson and Cardinal Health Comparative AnalysisJorge Santillan
The document provides an introduction to McKesson Corporation, describing its two business segments of pharmaceutical distribution and healthcare information technology solutions. It then states that a financial analysis of McKesson and one of its competitors, Cardinal Health, will be conducted using financial statements from 2013, 2012 and 2011 to determine which company would provide a better return on investment for investors. Descriptions of both McKesson and Cardinal Health are also provided.
Cardinal Health 2016 Annual Shareholder Meeting PresentationCardinal_Health
This document summarizes the annual shareholders meeting of Cardinal Health, Inc. held on November 3, 2016. It discusses Cardinal Health's transformation of healthcare delivery through various business lines and services. In fiscal year 2016, Cardinal Health achieved $121.5 billion in revenue, a 19% increase over the previous year. Non-GAAP diluted earnings per share were $5.24, a 20% increase. For fiscal year 2017, the company expects high single-digit revenue growth and non-GAAP diluted EPS between $5.40-$5.60.
bristol myerd squibb Bristol-Myers Squibb Company Reports Second Quarter 2008...finance13
Bristol-Myers Squibb reports strong financial performance in Q2 2008 with 16% growth in global net sales and 24% increase in pre-tax earnings. They reaffirmed 2008 EPS guidance and announced plans to achieve an additional $1 billion in productivity savings by 2012. Key drivers of growth were double-digit sales increases of drugs such as Plavix, Abilify, and the HIV/Hepatitis portfolio. Bristol-Myers Squibb also submitted regulatory filings for the diabetes drug Onglyza in the US and Europe.
This document summarizes Cardinal Health's investor and analyst meeting that took place on November 19, 2015. The agenda included an overview of healthcare strategy and financials, a discussion of the pharmaceutical and medical outlook, and a specialist physician panel. Cardinal Health's CEO discussed how the company is changing healthcare. Other presentations provided insights into healthcare trends, the consumer of 2020, value-based care, and Cardinal Health's financial performance and long-term growth aspirations.
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook finance3
P&G reported strong sales and earnings growth in the first quarter. Net sales increased 27% to $18.79 billion due to growth in both the base P&G business and the addition of Gillette. Organic sales grew 6% and earnings per share increased 3% to $0.79, though EPS growth excluding Gillette dilution was 9-10%. P&G increased its full-year earnings per share outlook due to better cost expectations and expects EPS growth of 13-14% for fiscal year 2007.
35th Annual J.P. Morgan Healthcare Conference PresentationCardinal_Health
George S. Barrett, Chairman and CEO of Cardinal Health, gave a presentation at the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017. In the presentation, Barrett discussed how Cardinal Health is changing healthcare by bringing scaled solutions to help customers navigate a complex industry. He outlined key trends shaping the next five years in healthcare and how Cardinal Health is positioned for growth and success through strategic priorities that align with these trends. Barrett also reviewed Cardinal Health's financial performance and goals over the past five years.
1) Quest Diagnostics had an excellent first quarter with revenues growing 18%, earnings per share growing 13%, and strong cash generation of $241 million.
2) The company is seeing benefits from investments in new and innovative tests that are enhancing its value proposition.
3) After consideration, Quest decided to discontinue operations at its struggling test kit manufacturing subsidiary NID, which will reduce ongoing losses but result in restructuring charges in the second quarter.
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...finance3
P&G reported strong quarterly results with 9% sales growth and 17% EPS growth. They also announced plans to create a standalone coffee company called Folgers Coffee Company by spinning it off or splitting it off from P&G. The coffee business generated $1.6B in sales in 2007. All business segments saw sales growth, led by Beauty and Health Care. For fiscal 2008, P&G expects 4-6% organic sales growth and 14-15% EPS growth.
The document provides an earnings summary and outlook for Q2 2016. Key points include:
- Adjusted EPS was above guidance despite a challenging macro environment.
- Transportation orders remained solid while Industrial orders grew quarter-over-quarter.
- Guidance for Q3 2016 projects adjusted EPS growth of 14% year-over-year.
- Full year 2016 guidance reiterates sales of $12.1-12.5 billion and adjusted EPS of $3.90-4.10.
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growthfinance3
- P&G reported 11% growth in diluted EPS to $0.82 driven by 9% net sales growth to $20.5 billion and 13% growth in operating profit. Volume grew 4% globally with 5% organic growth.
- Operating margin improved 0.6% through cost savings and synergies offsetting higher commodity costs. All segments saw sales growth with Beauty up 9% and Grooming up 13% on new product launches.
- The results demonstrated the benefits of P&G's diversification and focus on costs despite challenges, with cash flow well ahead of targets allowing $2.6 billion in share repurchases.
- McKesson Corporation reported strong financial performance for fiscal year 2005, with revenue growth of 16% to $80.5 billion, driven by new contracts with the VA and Caremark. Excluding litigation costs, earnings were $2.19 per share.
- The company transitioned agreements with pharmaceutical manufacturers to deliver more predictable compensation and address issues when drug price increases fell below expectations.
- All business segments grew, with the exception of Medical-Surgical Solutions which was impacted by lack of flu vaccine and litigation costs. Pharmaceutical Solutions and Provider Technologies performed well.
- Quest Diagnostics reported strong financial results for Q2 2006, with revenues increasing 15% and EPS growing to $0.78 excluding impacts from NID.
- Organic growth was driven by increases in gene-based women's health tests, cardiovascular tests, and allergy testing. The acquisition of Focus Diagnostics further strengthened esoteric testing.
- Guidance for 2006 was reiterated with revenues expected to grow 15% and operating income margins of 17.5%, excluding discontinued operations from NID.
Nielsen reported third quarter 2016 results with revenue up 3.6% to $1.57 billion driven by 6.7% growth in the Watch segment. Adjusted EBITDA was up 4% to $498 million and adjusted earnings per share increased 5.7% to $0.74. Free cash flow reached a record $353 million. Nielsen is executing on strategic initiatives such as Total Audience Measurement and saw continued momentum in areas like Digital Ad Ratings and Marketing Effectiveness. Guidance for 2016 was updated with revenue growth expected at 3.5-4% and adjusted EPS of $2.73-2.79.
P&G Delivers 15% Earnings Per Share Growth for Fiscal Yearfinance3
P&G reported strong financial results for the April-June quarter and full fiscal year. Sales increased 10% for both periods, while earnings per share grew 12% and 15%, respectively. Unit volume grew 6% for the quarter and 8% for the full year, with double-digit growth in beauty and healthcare. All business segments, regions, and top 16 brands saw sales increases. Higher commodity costs posed challenges but were partially offset by pricing actions and cost savings.
This document is Walgreens' 2008 annual report which provides the following key information:
- Walgreens is the largest drugstore chain in the US with fiscal 2008 sales of $59 billion and 237,000 employees.
- It was the company's 34th consecutive year of record sales and earnings.
- In 2008, Walgreens focused on serving customers better through programs like their Prescription Savings Club, streamlining products, and expanding private brands. They also contained costs and launched new cost initiatives targeting $1 billion in annual reductions.
- Walgreens adjusted their organic store growth target from 9% to 5% to allow more focus on improving customer experience and flexibility to invest in new opportunities. They are
Quest Diagnostics held a second quarter 2005 conference call to discuss financial results.
- Revenues grew 6.2% to $1.6 billion driven by a 5.3% increase in testing volume and a 1.2% increase in revenue per test.
- Earnings per share grew 14% to $0.59, and operating income margin expanded.
- Guidance for 2005 was reiterated with earnings per share growth of 14-16% and revenue growth of 5-6% expected.
Cardinal Health reported an 11% increase in revenue to $24 billion for the first quarter. Earnings per share declined 16% to $0.69 due to contract re-pricings and anti-diversion efforts. The healthcare supply chain services segment achieved double-digit revenue growth but profit declined 16% due to pricing issues. Clinical and medical products revenue grew 12% and profits grew 15% driven by continued strength in dispensing. Cardinal Health reiterated its full-year guidance range despite economic uncertainty.
J.P. Morgan 33rd Annual Healthcare ConferenceCardinal_Health
This document contains the transcript from George S. Barrett's presentation at the J.P. Morgan Healthcare Conference on January 13, 2015. It discusses Cardinal Health's strategic priorities including growing its specialty pharmaceutical, generic drug sourcing, and international businesses. It also outlines opportunities in health system solutions, alternate sites of care, and the home healthcare market. The presentation notes Cardinal Health's sustained financial performance and future aspirations for metrics like operating margin and earnings growth. It emphasizes the company's focus on key trends in healthcare like increased consumerism, transition to value-based care, and continued innovation.
P&G Delivers Results Above Expectations - Raises Fiscal Year Outlookfinance3
P&G reported financial results for the quarter ending December 2006 that were above expectations. Strong sales growth of P&G and newly acquired Gillette brands drove higher earnings per share despite costs associated with the Gillette acquisition. Net sales increased 27% to $18.34 billion due to a 27% increase in unit volume. Organic sales, excluding acquisitions and divestitures, grew 8%. Earnings per share were $0.72, in line with the prior year despite an estimated $0.06-$0.07 per share dilution from the Gillette acquisition. The company raised its full year earnings outlook based on the strong quarterly results and integration progress of Gillette.
J.P. Morgan 34th Annual Healthcare Conference PresentationCardinal_Health
This document is a presentation from Cardinal Health's Chairman and CEO George Barrett given at the J.P. Morgan Healthcare Conference on January 12, 2016. The presentation provides an overview of Cardinal Health, including key facts about the company, its two business segments and growth drivers, financial highlights and goals, capital deployment, and positioning in the changing healthcare industry. It emphasizes Cardinal Health's focus on serving customers across the care continuum.
- Cardinal Health reported financial results for Q1 FY2016 with revenue increasing 17% year-over-year to $28.1 billion and non-GAAP diluted EPS increasing 38% to $1.38.
- The Pharmaceutical segment saw a 19% revenue increase to $25.1 billion and a 46% increase in segment profit to $657 million due to growth from existing and new customers.
- The Medical segment reported a 2% revenue increase to $2.9 billion but an 11% decline in segment profit to $101 million primarily due to Cardinal Health's Canada business.
- For FY2016, Cardinal Health expects mid-teens revenue growth and non-GAAP diluted EPS between
McKesson and Cardinal Health Comparative AnalysisJorge Santillan
The document provides an introduction to McKesson Corporation, describing its two business segments of pharmaceutical distribution and healthcare information technology solutions. It then states that a financial analysis of McKesson and one of its competitors, Cardinal Health, will be conducted using financial statements from 2013, 2012 and 2011 to determine which company would provide a better return on investment for investors. Descriptions of both McKesson and Cardinal Health are also provided.
Cardinal Health 2016 Annual Shareholder Meeting PresentationCardinal_Health
This document summarizes the annual shareholders meeting of Cardinal Health, Inc. held on November 3, 2016. It discusses Cardinal Health's transformation of healthcare delivery through various business lines and services. In fiscal year 2016, Cardinal Health achieved $121.5 billion in revenue, a 19% increase over the previous year. Non-GAAP diluted earnings per share were $5.24, a 20% increase. For fiscal year 2017, the company expects high single-digit revenue growth and non-GAAP diluted EPS between $5.40-$5.60.
bristol myerd squibb Bristol-Myers Squibb Company Reports Second Quarter 2008...finance13
Bristol-Myers Squibb reports strong financial performance in Q2 2008 with 16% growth in global net sales and 24% increase in pre-tax earnings. They reaffirmed 2008 EPS guidance and announced plans to achieve an additional $1 billion in productivity savings by 2012. Key drivers of growth were double-digit sales increases of drugs such as Plavix, Abilify, and the HIV/Hepatitis portfolio. Bristol-Myers Squibb also submitted regulatory filings for the diabetes drug Onglyza in the US and Europe.
This document summarizes Cardinal Health's investor and analyst meeting that took place on November 19, 2015. The agenda included an overview of healthcare strategy and financials, a discussion of the pharmaceutical and medical outlook, and a specialist physician panel. Cardinal Health's CEO discussed how the company is changing healthcare. Other presentations provided insights into healthcare trends, the consumer of 2020, value-based care, and Cardinal Health's financial performance and long-term growth aspirations.
P&G Reports Strong Sales and Earnings Growth, Increases Fiscal Year Outlook finance3
P&G reported strong sales and earnings growth in the first quarter. Net sales increased 27% to $18.79 billion due to growth in both the base P&G business and the addition of Gillette. Organic sales grew 6% and earnings per share increased 3% to $0.79, though EPS growth excluding Gillette dilution was 9-10%. P&G increased its full-year earnings per share outlook due to better cost expectations and expects EPS growth of 13-14% for fiscal year 2007.
35th Annual J.P. Morgan Healthcare Conference PresentationCardinal_Health
George S. Barrett, Chairman and CEO of Cardinal Health, gave a presentation at the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017. In the presentation, Barrett discussed how Cardinal Health is changing healthcare by bringing scaled solutions to help customers navigate a complex industry. He outlined key trends shaping the next five years in healthcare and how Cardinal Health is positioned for growth and success through strategic priorities that align with these trends. Barrett also reviewed Cardinal Health's financial performance and goals over the past five years.
1) Quest Diagnostics had an excellent first quarter with revenues growing 18%, earnings per share growing 13%, and strong cash generation of $241 million.
2) The company is seeing benefits from investments in new and innovative tests that are enhancing its value proposition.
3) After consideration, Quest decided to discontinue operations at its struggling test kit manufacturing subsidiary NID, which will reduce ongoing losses but result in restructuring charges in the second quarter.
P&G Reports $0.98 EPS, Up 17%, on 9% Sales Growth; Announces Plan to Create S...finance3
P&G reported strong quarterly results with 9% sales growth and 17% EPS growth. They also announced plans to create a standalone coffee company called Folgers Coffee Company by spinning it off or splitting it off from P&G. The coffee business generated $1.6B in sales in 2007. All business segments saw sales growth, led by Beauty and Health Care. For fiscal 2008, P&G expects 4-6% organic sales growth and 14-15% EPS growth.
The document provides an earnings summary and outlook for Q2 2016. Key points include:
- Adjusted EPS was above guidance despite a challenging macro environment.
- Transportation orders remained solid while Industrial orders grew quarter-over-quarter.
- Guidance for Q3 2016 projects adjusted EPS growth of 14% year-over-year.
- Full year 2016 guidance reiterates sales of $12.1-12.5 billion and adjusted EPS of $3.90-4.10.
P&G Reports $0.82 EPS, Up 11%, On 13% Operating Profit Growthfinance3
- P&G reported 11% growth in diluted EPS to $0.82 driven by 9% net sales growth to $20.5 billion and 13% growth in operating profit. Volume grew 4% globally with 5% organic growth.
- Operating margin improved 0.6% through cost savings and synergies offsetting higher commodity costs. All segments saw sales growth with Beauty up 9% and Grooming up 13% on new product launches.
- The results demonstrated the benefits of P&G's diversification and focus on costs despite challenges, with cash flow well ahead of targets allowing $2.6 billion in share repurchases.
- McKesson Corporation reported strong financial performance for fiscal year 2005, with revenue growth of 16% to $80.5 billion, driven by new contracts with the VA and Caremark. Excluding litigation costs, earnings were $2.19 per share.
- The company transitioned agreements with pharmaceutical manufacturers to deliver more predictable compensation and address issues when drug price increases fell below expectations.
- All business segments grew, with the exception of Medical-Surgical Solutions which was impacted by lack of flu vaccine and litigation costs. Pharmaceutical Solutions and Provider Technologies performed well.
- Quest Diagnostics reported strong financial results for Q2 2006, with revenues increasing 15% and EPS growing to $0.78 excluding impacts from NID.
- Organic growth was driven by increases in gene-based women's health tests, cardiovascular tests, and allergy testing. The acquisition of Focus Diagnostics further strengthened esoteric testing.
- Guidance for 2006 was reiterated with revenues expected to grow 15% and operating income margins of 17.5%, excluding discontinued operations from NID.
Nielsen reported third quarter 2016 results with revenue up 3.6% to $1.57 billion driven by 6.7% growth in the Watch segment. Adjusted EBITDA was up 4% to $498 million and adjusted earnings per share increased 5.7% to $0.74. Free cash flow reached a record $353 million. Nielsen is executing on strategic initiatives such as Total Audience Measurement and saw continued momentum in areas like Digital Ad Ratings and Marketing Effectiveness. Guidance for 2016 was updated with revenue growth expected at 3.5-4% and adjusted EPS of $2.73-2.79.
P&G Delivers 15% Earnings Per Share Growth for Fiscal Yearfinance3
P&G reported strong financial results for the April-June quarter and full fiscal year. Sales increased 10% for both periods, while earnings per share grew 12% and 15%, respectively. Unit volume grew 6% for the quarter and 8% for the full year, with double-digit growth in beauty and healthcare. All business segments, regions, and top 16 brands saw sales increases. Higher commodity costs posed challenges but were partially offset by pricing actions and cost savings.
This document is Walgreens' 2008 annual report which provides the following key information:
- Walgreens is the largest drugstore chain in the US with fiscal 2008 sales of $59 billion and 237,000 employees.
- It was the company's 34th consecutive year of record sales and earnings.
- In 2008, Walgreens focused on serving customers better through programs like their Prescription Savings Club, streamlining products, and expanding private brands. They also contained costs and launched new cost initiatives targeting $1 billion in annual reductions.
- Walgreens adjusted their organic store growth target from 9% to 5% to allow more focus on improving customer experience and flexibility to invest in new opportunities. They are
Quest Diagnostics held a second quarter 2005 conference call to discuss financial results.
- Revenues grew 6.2% to $1.6 billion driven by a 5.3% increase in testing volume and a 1.2% increase in revenue per test.
- Earnings per share grew 14% to $0.59, and operating income margin expanded.
- Guidance for 2005 was reiterated with earnings per share growth of 14-16% and revenue growth of 5-6% expected.
Cardinal Health reported an 11% increase in revenue to $24 billion for the first quarter. Earnings per share declined 16% to $0.69 due to contract re-pricings and anti-diversion efforts. The healthcare supply chain services segment achieved double-digit revenue growth but profit declined 16% due to pricing issues. Clinical and medical products revenue grew 12% and profits grew 15% driven by continued strength in dispensing. Cardinal Health reiterated its full-year guidance range despite economic uncertainty.
This document summarizes a conference call by Quest Diagnostics about their third quarter 2005 financial results. Key points include:
- Revenues grew 6.4%, earnings per share were $0.66, and cash flow was $178 million.
- Clinical testing revenues grew 7.1% due to increased volume and revenue per test. Hurricanes Katrina and Rita reduced revenues by 0.5%.
- Operating income was 17.7% of revenues compared to 18% last year. Margins increased in clinical testing but were reduced by hurricanes and a $6.2 million charge.
- Their test kit manufacturing subsidiary NID performed below last year, reducing revenue growth by 0.5% and margin expansion
P&G Reports 8% Net Sales and 22% EPS Growth in the Fourth Quarter finance3
The Procter & Gamble Company reported 8% net sales growth and 22% earnings per share growth in the fourth quarter. P&G also announced plans to repurchase $24-30 billion of company shares over the next three years through increased share buybacks of $8-10 billion annually. Every business segment grew organic sales for the fiscal year, led by high-single digit growth in blades and razors and fabric and home care. Chairman A.G. Lafley expressed confidence in P&G's strategies and ability to take advantage of growth opportunities.
- Cardinal Health reported financial results for its third quarter of fiscal year 2018, ending March 31, 2018.
- Total revenue increased 6% year-over-year to $33.6 billion. However, operating earnings decreased 10% to $546 million and net earnings decreased 33% to $255 million.
- The Pharmaceutical segment saw a 5% increase in revenue driven by sales growth, but segment profit decreased due to generic program performance. The Medical segment had a 15% revenue increase from acquisitions, and a 34% increase in segment profit.
- For fiscal year 2018, Cardinal Health expects revenue to increase by a mid-single digit percentage and non-GAAP EPS to be between $
bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...finance13
Bristol-Myers Squibb reported strong financial results for the first quarter of 2008, with net sales growing 20% driven by growth in the pharmaceutical business. Earnings from continuing operations grew 51% to $1.29 billion compared to the first quarter of 2007. The company reaffirmed its 2008 earnings guidance and announced plans to file an IPO to sell approximately 10% of its Mead Johnson Nutritionals business. Key drugs such as Abilify, Plavix, and Baraclude saw sales increases in the double-digit percentages compared to the first quarter of 2007.
Quest Diagnostics held a conference call to discuss financial results for the third quarter of 2008. Key points included:
- Revenues grew 3.4% to $1.8 billion, adjusted earnings per share increased 12%, and cash flow improved to $329 million.
- Guidance for full year 2008 was raised for adjusted earnings per share to between $3.17-$3.22.
- The company reached an agreement in principle with the federal government regarding an investigation, increasing related reserves by $73 million.
- Growth was driven by increases in esoteric, gene-based, and routine testing. Progress was also made on cost reduction initiatives.
P&G Delivers Double-Digit Sales Growth in First Quarterfinance3
P&G reported double-digit sales growth in the first quarter, exceeding Wall Street earnings estimates. Unit volume grew 13% driven by double-digit growth in fabric and home care and health care. Net sales increased 11% to $10.8 billion. Core earnings per share grew 17% to $1.12 per share, beating consensus estimates by two cents. The company expects high single-digit volume growth and mid to upper single-digit sales growth in the second quarter. For the fiscal year, sales growth of 4-6% and double-digit earnings per share growth are expected.
Pitney Bowes reported third quarter 2008 results with revenue increasing 3% to $1.5 billion and adjusted income from continuing operations of $139 million. On a GAAP basis, income from continuing operations was $100 million and net income was $98 million. Adjusted earnings per share were $0.67 compared to $0.63 in the prior year. For the full year, the company expects free cash flow to exceed $800 million and adjusted earnings per share between $2.75 to $2.82.
UnitedHealth Group reported record third quarter results in 2006, with net earnings of $0.79 per share, up 30% from the previous year. Revenues increased 55% to $18 billion due to acquisitions and organic growth. Operating margin was 10.3% as growth was matched with cost management. The company expects full-year EPS growth of at least 25% and projects 2007 EPS growth of 15% over projected 2006 EPS of $2.95 to $2.97.
P&G Delivers 15% EPS Growth - Raises Fiscal Year Guidancefinance3
- P&G reported 15% earnings per share growth for the January-March quarter, above analysts' estimates, driven by strong organic sales growth despite a difficult operating environment.
- Net sales increased 10% to $14.29 billion for the quarter, with organic sales growth of 8%, above P&G's target range.
- As a result of the strong results, P&G raised its fiscal year earnings per share guidance range to $2.64 to $2.65.
United Health Group[PDF Document] Earnings Releasefinance3
UnitedHealth Group reported first quarter 2008 results, with revenues increasing 7% to $20.3 billion and people served growing by 2 million to 73 million. Operating margin was 8.4% and net earnings per share grew 5% to $0.78. However, the company reduced its full-year 2008 outlook by 10% to a range of $3.55-$3.60 per share due to higher than expected medical costs and lower investment income. The company remains committed to $4 billion in share repurchases for 2008.
Aetna reported its second-quarter 2006 results, with the following key highlights:
- Operating earnings per share of $0.65, up 23% from the prior year, and in line with estimates. Total revenues increased 14% to $6.3 billion.
- Full-year 2006 operating earnings per share guidance increased to a range of $2.77 to $2.79 per share, up from prior guidance.
- Certain areas like a large government case and stop-loss product underperformed due to higher than expected large claims. The commercial risk medical cost ratio was 81.4%, excluding development.
- Membership increased year-over-year but declined slightly sequentially, to
UnitedHealth Group reported record first quarter results for 2006, with net earnings of $0.63 per share, up 15% from the first quarter of 2005. Revenue increased 54% to over $17 billion compared to the same period last year. The company also increased its full year 2006 earnings per share outlook to a range of $2.88 to $2.92, representing growth of 22-24% over 2005. Strong growth was driven by the company's businesses serving seniors, commercial services including consumer-driven healthcare plans, and specialty businesses.
Cardinal Health Q4 FY 2016 Earnings PresentationCardinal_Health
- Cardinal Health reported Q4 FY2016 revenue of $31.4 billion, a 14% increase over Q4 FY2015. Operating earnings increased 11% to $620 million.
- For FY2016, Cardinal Health reported record revenue of $121.5 billion, a 19% increase over FY2015. Operating earnings increased 14% to $2.5 billion.
- For FY2017, Cardinal Health expects revenue to increase in the high-single digit percentage range compared to FY2016. Non-GAAP diluted EPS is expected to be between $5.48 to $5.73.
Cardinal Health Q3 FY 2016 Earnings PresentationCardinal_Health
- Cardinal Health reported revenue of $30.7 billion for Q3 FY2016, a 21% increase over the previous year. Operating earnings increased 11% to $656 million.
- Revenue growth was driven by contributions from acquisitions as well as growth with new and existing customers in both the Pharmaceutical and Medical segments.
- The company updated full-year FY2016 guidance, expecting revenue growth in the mid- to high-teens percentage range over FY2015 and non-GAAP diluted EPS between $5.17 to $5.27.
UnitedHealth Group reported strong financial results for the first quarter of 2009. Revenues increased 8% year-over-year to $22 billion driven by growth in risk-based offerings. Net earnings of $0.81 per share were up 4% year-over-year. Cash flows from operations more than tripled to $1.1 billion. The company continues to project full-year 2009 net earnings of $2.90 to $3.15 per share and cash flows from operations of approximately $5 billion.
Strong Volume and Operating Margin Improvements Drive Earnings Growthfinance3
P&G reported strong financial results for the quarter ended December 31, 2002, with unit volume growth of 8% and core earnings per share growth of 10%. Volume growth was driven by double-digit increases in health care and beauty care. Gross margins expanded 140 basis points due to base business savings and lower material costs. For the fiscal year, P&G expects sales growth at the top end of its 4-6% target range and earnings per share growth of 12-13%.
- Cardinal Health reported Q4 FY2017 revenue of $32.966 billion, a 5% increase over the prior year. Operating earnings were $439 million, a 29% decrease.
- Revenue in the Pharmaceutical segment increased 5% to $29.552 billion driven by distribution customer and specialty solutions growth. Segment profit decreased 7% to $505 million due to generic pricing and IT investment.
- The Medical segment saw 6% revenue growth to $3.416 billion from new and existing customers. Segment profit rose 13% to $138 million from post-acute solutions and distribution growth.
United Health Group [PDF Document] Earnings Releasefinance3
UnitedHealth Group reported record second quarter results for 2006, with GAAP net earnings of $0.70 per share, a 21% increase over the second quarter of 2005. Revenues increased 57% year-over-year to nearly $18 billion. The operating margin expanded to 9.1% and operating cash flows were $1.7 billion. UnitedHealth Group increased its earnings per share growth outlook for 2006 to 23-25% and expects baseline EPS to increase 15% in 2007. Business segments like Health Care Services and Uniprise saw revenue and membership growth across key areas.
Similar to cardinal health Q4 2008 Earnings Release (20)
The Home Depot Celebrates Hispanic Culture Through Color and Paint With Color...finance2
The Home Depot launched a new Hispanic-inspired paint color palette called Colores Origenes, featuring over 70 vibrant colors with Spanish names to reflect Latin American culture. Research showed painting is very popular among Hispanics, 59% of whom speak Spanish at home. The new paint line and increased Spanish signage and materials aim to better serve the growing Hispanic community. It was created with Behr Paint and will be sold exclusively at select Home Depot stores.
The Home Depot and AARP Launch Nationwide Workshopsfinance2
The Home Depot and AARP launched nationwide home improvement workshops customized for those aged 50 and over. The workshops will cover topics like home modifications for comfort and safety, saving money on energy bills, and basic maintenance. The workshops are part of an alliance between the two organizations to provide resources for aging homeowners as around 86 million Americans are currently over 50, comprising over 40% of the population.
Nearly Half of Americans Fail to Check Home Safety Devices at Daylight-Saving...finance2
A survey found that 47% of Americans did not check their home safety devices when changing their clocks for daylight saving time last year. Nearly three-quarters did not know when daylight saving time ends this year on October 30th. The Home Depot recommends using the end of daylight saving time as a reminder to check smoke detectors and carbon monoxide detectors by changing their batteries.
View Summary The Home Depot Celebrates the Olympic Spirit With Special Kids...finance2
The Home Depot announced a special Olympic-themed Kids Workshop to be held on November 5, 2005 at its stores nationwide. Children will build a wooden bobsled toy to celebrate the 2006 Winter Olympics. Selected stores will host Olympic athletes to help children and promote the Olympics. The Home Depot aims to teach kids DIY skills through these monthly workshops and has hosted over 13 million children since 1997.
The Home Depot Announces First Quarter Resultsfinance2
The Home Depot reported first quarter earnings of $356 million, down from $1 billion in the same period last year. This included a $543 million non-recurring charge for closing underperforming stores. Excluding this charge, earnings were $697 million. Sales decreased 3.4% to $17.9 billion due to a 6.5% drop in comparable store sales. The company's CEO acknowledged difficult market conditions and said the company would focus on investing in existing stores.
1) The document discusses Home Depot's merchandising strategy, which focuses on national brands, exclusive proprietary brands, and serving core customers through product knowledge transfer.
2) Home Depot aims to aggressively attack the market through its brand strategies, which leverage national brands, exclusive brands, and proprietary brands to differentiate, build preference, and offer selection.
3) Home Depot is transforming its merchandising approach through investments in talent, focused processes like seasonal planning and presentation, and new systems that provide merchants better data and tools.
home depot 2008 Annual Meeting of Stockholdersfinance2
This document summarizes The Home Depot's 2008 Annual Meeting of Shareholders. It provides an overview of the company's financial performance in 2007, including a 2% decrease in sales and an 11% decrease in net earnings per share. It also outlines the company's five priorities for 2007 which were investing in associate engagement, shopping environment, product availability, product excitement, and owning the professional customer. The outlook anticipates 2008 will be another difficult year with guidance for a 4-5% sales decrease and a 19-24% decrease in earnings per share. The company will continue investing in its key priorities and allocating capital efficiently.
The document is a transcript from The Home Depot's 2008 Investor Day conference. Frank Blake, the company's CEO, provides an overview of the company's strategic focus on improving the core retail business, exercising disciplined capital allocation, increasing returns on existing assets, and building sustained competitive advantages. He highlights progress made on priorities like associate engagement and product availability. While housing market conditions remain difficult, Blake emphasizes the company's long term strategy and goals, such as becoming a best in class merchandiser.
This document provides a financial overview and discussion of Home Depot's performance in Q1 2008 and outlook for 2008. Some key points:
- Q1 2008 sales were down 3.4% and operating income was down 56.5% due to housing market challenges.
- For 2008, Home Depot expects total sales to decline 4-5%, negative comps in the mid-to-high single digits, and operating margin decline of 170-210 basis points.
- Home Depot has a staggered debt maturity schedule with low refinancing risk and strong cash flow and liquidity.
- The company is focused on capital efficiency through store rationalization, supply chain improvements, and driving productivity across operations
Paul Raines discusses Home Depot's focus on store operations and customers. Key points include:
1) Home Depot has made multi-year investments to improve labor standards, launch an "Aprons on the Floor" program, and focus on foundational improvements like maintenance and store standards.
2) The company is focusing on two customer segments - professional contractors and multicultural customers - through programs like product knowledge certification for associates, understanding each group's purchasing patterns, and targeted marketing.
3) Initiatives like daytime freight, call center closures, and a new merchandising team have helped exceed Home Depot's $180 million goal in operating cost reductions to reinvest in labor.
home depot http://ir.homedepot.com/common/download/download.cfm?companyid=HD&...finance2
This document discusses Home Depot's supply chain transformation efforts from 2007 to 2008. It outlines goals of improving product availability, inventory management, and developing an optimal distribution network. Home Depot implemented regional distribution centers (RDCs) to better aggregate store orders, improve in-stock levels, and reduce supply chain costs. The RDCs were shown to simplify operations and had benefits including increased gross margins and improved inventory turns that could generate $1.5 billion in additional cash.
The document discusses a decline in private residential investment and subprime/Alt-A mortgages over the past few years which has negatively impacted the housing market. It then outlines Home Depot's strategic focus on increasing returns through disciplined capital allocation, investing in existing assets like employee training and supply chain improvements, and building sustained competitive advantages. Home Depot expects another difficult year in 2008 but believes these strategic initiatives position it for stronger future growth once market conditions normalize.
home depotForward Looking & Non-GAAP Disclosures finance2
The document discusses forward-looking statements made in today's presentations regarding the home improvement and housing markets, earnings guidance, and other factors affecting earnings and sales. It notes these statements are based on currently available information and expectations that could change. It also discusses non-GAAP financial measurements included in today's presentations, including total adjusted debt and earnings measures that exclude expected costs associated with store closures and pipeline changes. These supplemental measures are not a substitute for GAAP but provide useful information to investors.
home depot Bank of America 38th Annual Investment Conferencefinance2
Carol Tomé and Mark Holifield presented at the Bank of America 38th Annual Investment Conference. The presentation discussed (1) Home Depot's progress on five priorities including implementing store standards and supply chain improvements, (2) the evolution of Home Depot's capital efficiency strategy through investing in priorities and rationalizing non-core assets, and (3) expected benefits from supply chain improvements including gross margin expansion and $1.5 billion additional cash from reducing inventory turns.
- The Home Depot reported third quarter earnings for fiscal year 2008, with sales of $17.8 billion, down 6.2% from the previous year, and same-store sales down 8.3%. Earnings per share were $0.45.
- Challenging housing and home improvement markets continued to pressure results. Previously strong regions like the Northwest saw double-digit negative comps.
- While sales were weak across most departments, building materials had positive comps led by roofing and insulation. Initiatives to improve merchandising and focus on value are showing early signs of success through improved transactions, market share gains, and gross margin expansion despite volatile costs.
- Tightening credit availability also
- The Home Depot reported third quarter earnings for fiscal year 2008, with sales of $17.8 billion, down 6.2% from the previous year, and same-store sales down 8.3%. Earnings per share were $0.45.
- Challenging housing and home improvement markets continued to pressure results. Previously strong regions like the Northwest saw double-digit negative comps.
- While sales were weak across most departments, building materials had positive comps led by roofing and insulation. Initiatives to improve merchandising and focus on value are showing early signs of success through improved transactions, market share gains, and gross margin expansion despite volatile costs.
- Tightening credit availability also
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby...Donc Test
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting, 8th Canadian Edition by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Ebook Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Pdf Solution Manual For Financial Accounting 8th Canadian Edition Pdf Download Stuvia Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Financial Accounting 8th Canadian Edition Ebook Download Stuvia Financial Accounting 8th Canadian Edition Pdf Financial Accounting 8th Canadian Edition Pdf Download Stuvia
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
BONKMILLON Unleashes Its Bonkers Potential on Solana.pdfcoingabbar
Introducing BONKMILLON - The Most Bonkers Meme Coin Yet
Let's be real for a second – the world of meme coins can feel like a bit of a circus at times. Every other day, there's a new token promising to take you "to the moon" or offering some groundbreaking utility that'll change the game forever. But how many of them actually deliver on that hype?
Financial Assets: Debit vs Equity Securities.pptxWrito-Finance
financial assets represent claim for future benefit or cash. Financial assets are formed by establishing contracts between participants. These financial assets are used for collection of huge amounts of money for business purposes.
Two major Types: Debt Securities and Equity Securities.
Debt Securities are Also known as fixed-income securities or instruments. The type of assets is formed by establishing contracts between investor and issuer of the asset.
• The first type of Debit securities is BONDS. Bonds are issued by corporations and government (both local and national government).
• The second important type of Debit security is NOTES. Apart from similarities associated with notes and bonds, notes have shorter term maturity.
• The 3rd important type of Debit security is TRESURY BILLS. These securities have short-term ranging from three months, six months, and one year. Issuer of such securities are governments.
• Above discussed debit securities are mostly issued by governments and corporations. CERTIFICATE OF DEPOSITS CDs are issued by Banks and Financial Institutions. Risk factor associated with CDs gets reduced when issued by reputable institutions or Banks.
Following are the risk attached with debt securities: Credit risk, interest rate risk and currency risk
There are no fixed maturity dates in such securities, and asset’s value is determined by company’s performance. There are two major types of equity securities: common stock and preferred stock.
Common Stock: These are simple equity securities and bear no complexities which the preferred stock bears. Holders of such securities or instrument have the voting rights when it comes to select the company’s board of director or the business decisions to be made.
Preferred Stock: Preferred stocks are sometime referred to as hybrid securities, because it contains elements of both debit security and equity security. Preferred stock confers ownership rights to security holder that is why it is equity instrument
<a href="https://www.writofinance.com/equity-securities-features-types-risk/" >Equity securities </a> as a whole is used for capital funding for companies. Companies have multiple expenses to cover. Potential growth of company is required in competitive market. So, these securities are used for capital generation, and then uses it for company’s growth.
Concluding remarks
Both are employed in business. Businesses are often established through debit securities, then what is the need for equity securities. Companies have to cover multiple expenses and expansion of business. They can also use equity instruments for repayment of debits. So, there are multiple uses for securities. As an investor, you need tools for analysis. Investment decisions are made by carefully analyzing the market. For better analysis of the stock market, investors often employ financial analysis of companies.
5 Tips for Creating Standard Financial ReportsEasyReports
Well-crafted financial reports serve as vital tools for decision-making and transparency within an organization. By following the undermentioned tips, you can create standardized financial reports that effectively communicate your company's financial health and performance to stakeholders.
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
Independent Study - College of Wooster Research (2023-2024) FDI, Culture, Glo...AntoniaOwensDetwiler
"Does Foreign Direct Investment Negatively Affect Preservation of Culture in the Global South? Case Studies in Thailand and Cambodia."
Do elements of globalization, such as Foreign Direct Investment (FDI), negatively affect the ability of countries in the Global South to preserve their culture? This research aims to answer this question by employing a cross-sectional comparative case study analysis utilizing methods of difference. Thailand and Cambodia are compared as they are in the same region and have a similar culture. The metric of difference between Thailand and Cambodia is their ability to preserve their culture. This ability is operationalized by their respective attitudes towards FDI; Thailand imposes stringent regulations and limitations on FDI while Cambodia does not hesitate to accept most FDI and imposes fewer limitations. The evidence from this study suggests that FDI from globally influential countries with high gross domestic products (GDPs) (e.g. China, U.S.) challenges the ability of countries with lower GDPs (e.g. Cambodia) to protect their culture. Furthermore, the ability, or lack thereof, of the receiving countries to protect their culture is amplified by the existence and implementation of restrictive FDI policies imposed by their governments.
My study abroad in Bali, Indonesia, inspired this research topic as I noticed how globalization is changing the culture of its people. I learned their language and way of life which helped me understand the beauty and importance of cultural preservation. I believe we could all benefit from learning new perspectives as they could help us ideate solutions to contemporary issues and empathize with others.
Applying the Global Internal Audit Standards_AIS.pdf
cardinal health Q4 2008 Earnings Release
1. 7000 Cardinal Place
Dublin, OH 43017
www.cardinalhealth.com
FOR IMMEDIATE RELEASE
Contacts:
Media: Jim Mazzola Investors: Sally Curley
(614) 757-3690 (614) 757-7115
jim.mazzola@cardinalhealth.com sally.curley@cardinalhealth.com
CARDINAL HEALTH REPORTS FISCAL 2008 RESULTS,
PROVIDES FISCAL 2009 OUTLOOK
COMPANY EXPLORING SPIN-OFF OF CLINICAL AND MEDICAL PRODUCTS BUSINESSES
• Annual revenue increases 5 percent to $91 billion
• GAAP diluted earnings per share from continuing operations increase
76 percent to $3.64 and 11 percent to $3.80 on a non-GAAP basis
• Fourth quarter revenue increases 3 percent to $23 billion, GAAP diluted
earnings per share from continuing operations increase 51 percent to
$0.92 and 9 percent to $0.97 on a non-GAAP basis
• Reserve taken in connection with settlement discussions with Drug
Enforcement Administration
• Fiscal 2009 non-GAAP earnings per share expected to be $3.80 to $3.95 as
company makes significant investments in R&D, IT
DUBLIN, Ohio, Aug. 7, 2008 —Cardinal Health, a global provider of products and services that
improve the safety and productivity of health care, today reported an increase in fiscal 2008 revenue
of 5 percent to $91 billion and a 76 percent increase in GAAP earnings per share (EPS) to $3.64.
On a non-GAAP basis, EPS grew 11 percent to $3.801 for the year.
As the company had forecasted, the medical supply chain segment improved profit in the second half
of the year, driven by double-digit growth in its core U.S. medical distribution business. Significant
steps were taken in the pharmaceutical distribution business during the year to accelerate a recovery,
which the company expects in the second half of fiscal 2009.
Results during the quarter and year continued to highlight growth within the company’s medical
technology segments. Combined revenue for the Clinical Technologies and Services, and Medical
Products and Technologies segments grew by 24 percent to $5.6 billion and profit increased 36
percent to nearly $800 million for the year.
Cardinal Health also announced that its board of directors has supported a management
recommendation to actively explore a potential separation of the company’s primary operating and
reporting segments, which could involve a tax-free spin-off of the clinical and medical products
-more-
2. Cardinal Health News
Page 2
businesses as a separate, publicly traded company. Cardinal Health plans to announce its decision
within approximately 60 to 90 days.
“For two years, we have been taking steps to sharpen our focus on health care supply chain services
and clinical and medical products, culminating with our announcement in July to operate these
businesses in two distinct segments that reflect the unique characteristics and requirements of each,”
said R. Kerry Clark, chairman and chief executive officer of Cardinal Health. “As we now consider a
spin-off of our clinical and medical products businesses, our goal is simple: to have two thriving
businesses, delivering maximum value to customers and shareholders over the long term.”
Fiscal 2008 Results
Consolidated revenue for fiscal 2008 grew 5 percent to $91 billion and GAAP earnings from
continuing operations rose 58 percent to $1.3 billion. Diluted earnings per share from continuing
operations grew 76 percent to $3.64, or 11 percent to $3.80 on a non-GAAP basis. Earnings in the
prior year were negatively affected by a $600 million expense to resolve securities litigation.
During the fourth quarter, ended June 30, consolidated revenue increased 3 percent to $23 billion,
and earnings from continuing operations increased 39 percent to $330 million. Earnings in the fourth
quarter of the prior year were dampened by merger-related charges from the company’s acquisition
of VIASYS Healthcare. Excluding the impact of merger charges and other items, non-GAAP earnings
from continuing operations increased 1 percent to $348 million2, or 9 percent to $0.97 on a diluted per-
share basis.
“Overall, fourth quarter results were in line with our expectations,” Clark said. “We continued to
demonstrate to customers the value of our clinically differentiated medical technologies, where we
delivered a year of very strong growth on the top and bottom lines. We also made steady progress
throughout the year in our medical supply chain segment and, in particular, are very pleased with the
results in our hospital, lab and ambulatory care distribution business.
“In our pharmaceutical supply chain segment, we believe we are on the right path to resolve the
license suspensions that have kept us from distributing controlled substances from three of our 24
distribution centers. This will be a critical step in our efforts to drive improvements in the business.
And while we won’t speculate on the ultimate outcome, we are in constructive settlement discussions
with the DEA and have recorded a reserve of $23.5 million in connection with those discussions. We
have made good progress in enhancing our controls and are eager to return to full service levels for
our customers.”
Q4 and FY08 Summary
Q4 FY08 Q4 FY07 Y/Y FY08 Y/Y
Revenue $23 billion $22 billion 3% $91 billion 5%
Operating Earnings $543 million $421 million 29% $2.1 billion 55%
Non-GAAP Operating
Earnings3 $568 million $538 million 6% $2.2 billion 3%
Earnings from Continuing
Operations $330 million $238 million 39% $1.3 billion 58%
Non-GAAP Earnings from
Continuing Operations $348 million $345 million 1% $1.4 billion -
Diluted EPS from
Continuing Operations $0.92 $0.61 51% $3.64 76%
Non-GAAP Diluted EPS
from Continuing Operations $0.97 $0.89 9% $3.80 11%
-more-
3. Cardinal Health News
Page 3
Fourth-quarter and full-year segment results
Revenue for the Healthcare Supply Chain Services – Pharmaceutical segment increased 1
percent to $19.8 billion for the quarter with sales to bulk customers increasing by 9 percent. Sales to
non-bulk customers decreased by 5 percent, primarily due to the transfer of volume from non-bulk to
bulk sales by a large customer and the loss of business associated with controlled substance anti-
diversion efforts. As expected, segment profit declined 15 percent to $258 million, driven by previously
disclosed customer re-pricings, and direct-store-door customer losses, including the impact of anti-
diversion efforts. The profit decline was partially offset by branded pharmaceutical price increases and
greater profit from distribution service agreement fees.
For the year, segment revenue reached $79.3 billion, an increase of 4 percent, and segment profit
was $1.1 billion, declining 14 percent from last year.
Fourth-quarter revenue for the Healthcare Supply Chain Services – Medical segment increased
8 percent to $2.1 billion, driven by increased sales to existing hospital, laboratory and ambulatory
customers. Segment profit for the quarter decreased 3 percent to $81 million, but included a
previously disclosed corporate allocation adjustment that reduced profit by 6 percentage points.
Strong, double-digit profit growth from the distribution of medical and surgical products in the U.S.
partially offset the decline in segment profit from other factors. As the company had forecasted,
segment profit grew in the second half of fiscal 2008 compared to the second half of fiscal 2007.
Full-year revenue for the segment increased 8 percent to $8.1 billion, and full-year profit declined
5 percent to $303 million.
The Medical Products and Technologies segment reported a 46 percent increase in fourth-quarter
revenue to $727 million, primarily driven by the acquisitions of VIASYS Healthcare and Enturia, but
also organic growth in the core infection prevention and respiratory businesses. Segment profit
increased 63 percent to $95 million and included a favorable impact of 38 percentage points from
acquisitions. During the quarter, the company discovered it had failed to recognize profit on a portion
of intercompany sales from fiscal 2006 to 2008. As a result, approximately $16 million was recorded
as income for the fourth quarter that pertained to prior periods. The VIASYS integration continues to
be ahead of schedule to achieve planned synergy goals by 2010.
For the full year, segment revenue increased 47 percent to $2.7 billion and segment profit grew
52 percent to $300 million, including 39 percentage points from acquisitions.
Compared to a record quarter in the prior year, fourth-quarter revenue for the Clinical Technologies
and Services segment increased 3 percent to $780 million, driven by continued strength in
installations of medication dispensing products. Excluding Pharmacy Services, revenue increased
9 percent. Segment profit for the quarter exceeded company expectations, rising 8 percent to $156
million driven by favorable product mix and a positive impact from foreign exchange.
Full-year revenue for the segment increased 8 percent to $2.9 billion and segment profit increased
29 percent to $497 million.
Additional fourth-quarter and recent highlights include:
• Reaching a definitive agreement to sell Tecomet, a maker of orthopedic implants, to Charlesbank
Capital Partners and Tecomet management, with plans to close within 60 days;
• Reaching a definitive agreement to acquire Borschow Medical and Hospital Supplies, Inc., the
largest distributor of pharmaceutical products and medical supplies in Puerto Rico;
-more-
4. Cardinal Health News
Page 4
• Completing the acquisition of assets of privately held Enturia, Inc., the manufacturer of infection
prevention products sold under the ChloraPrep® brand name;
• Introducing the Pyxis® DuoStation, a new system that leverages the company’s industry-leading
dispensing technologies to enable clinicians access to a patient’s medications and medical
supplies from one system;
• Launching four new offerings for retail independent pharmacies at the company’s 19th annual
Retail Business Conference, including a private-label brand of durable medical equipment, front-
of-store management system, automated calling technology and automated pill counting
systems;
• A three-year agreement to serve as primary supply chain partner for Prime Therapeutics, one
of the nation’s largest pharmacy benefit managers, which serves approximately 14.6 million
members nationwide;
• Contracts with Premier for Alaris® infusion systems, Presource® custom procedure packs,
Convertors® surgical drapes and gowns, third-party instrument repair, respiratory equipment,
Pyxis® medication and supply automation products, and ChloraPrep® brand chlorhexidine
gluconate (CHG) skin prep products.
Outlook
“In fiscal 2009, we plan to make incremental investments of up to $100 million to strengthen R&D in
the clinical and medical products business and improve information technology in the supply chain
services business,” Clark said. “These investments will affect our earnings growth rates in fiscal
2009, but are important, foundational moves that we believe will accelerate future growth in both
segments.”
For fiscal 2009, the company expects revenue growth of 6 to 7 percent. Non-GAAP diluted EPS
from continuing operations is expected to be in a range of $3.80 to $3.95 based on investments the
company plans to make in new product development and information technology, and previously
disclosed challenges in the pharmaceutical distribution business that are expected to continue
through the first half of the fiscal year, coupled with a particularly unfavorable comparison in the first
quarter due to strong branded price inflation in the prior year period.
As a result, non-GAAP EPS in the first quarter is expected to be around $0.70. The company
forecasts EPS to return to more normal levels in the second quarter, with overall company results
stronger in the second half of the year.
Fiscal 2009 Financial Goals
6-7%
Revenue Growth
$3.80 - $3.95
Non-GAAP EPS
Segment Revenue Growth Profit Growth
Healthcare Supply Chain >6% Flat to (5%)
Services
Clinical and Medical Products >10% >20%
(Please reference the company’s slide presentation for corporate and segment assumptions related to
fiscal 2009 guidance, including that the potential separation of the clinical and medical products
businesses does not occur during fiscal 2009. The presentation is posted on the Investor page at
www.cardinalhealth.com).
-more-
5. Cardinal Health News
Page 5
The Healthcare Supply Chain Services segment is expected to return to profitable growth in the
second half of the year. The first half of the year will continue to be affected by the company’s ability
to resolve license suspensions to distribute controlled substances from three of its pharmaceutical
distribution centers, previously disclosed repricing of some major contracts and volatility in the
Nuclear Pharmacy Services business leading to the launch of generic sestimibi.
The Clinical and Medical Products segment is expected to continue on a strong growth trajectory
based on momentum in current product lines and approximately 50 new product introductions or
enhancements planned during the next 18 months.
Conference Call
Cardinal Health will host a conference call and webcast at 8:30 a.m. EDT to discuss the results.
To access the call and corresponding slide presentation, go to the Investor page at
www.cardinalhealth.com. The conference call may also be accessed by calling 617-213-4850,
conference passcode 97674427. An audio replay will be available until 11 p.m. EDT on Aug. 9 at
617-801-6888, passcode 28260453. A transcript and audio replay will also be available at
www.cardinalhealth.com.
About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $91 billion, global company
serving the health care industry with products and services that help hospitals, physician offices and
pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to
patients. With a focus on making supply chains more efficient, reducing hospital-acquired infections
and breaking the cycle of harmful medication errors, Cardinal Health develops market leading
technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, MedMined™
infection surveillance services and the CareFusion™ patient identification system. The company also
manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals
and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more
than 40,000 people on five continents. More information about the company may be found at
www.cardinalhealth.com.
###
1
Non-GAAP diluted EPS from continuing operations: Non-GAAP earnings from continuing operations
divided by diluted weighted average shares outstanding.
2
Non-GAAP earnings from continuing operations: Earnings from continuing operations excluding special
items and impairment charges and other, both net of tax.
3
Non-GAAP operating earnings: Operating earnings excluding special items and impairment charges and
other.
A reconciliation of the differences between these non-GAAP financial measures and their most directly
comparable GAAP financial measures is provided in the attached tables and at http://www.cardinalhealth.com.
This news release contains forward-looking statements addressing expectations, prospects, estimates and other
matters that are dependent upon future events or developments. These matters are subject to risks and
uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The
most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K
reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited
-more-
6. Cardinal Health News
Page 6
to) the following: uncertainties regarding the decision to explore the separation of the company’s clinical and
medical products businesses and regarding the impacts of such decision if the separation is accomplished;
competitive pressures in Cardinal Health’s various lines of business; the loss of one or more key customer or
supplier relationships or changes to the terms of those relationships; uncertainties relating to timing of generic
and branded pharmaceutical introductions and the frequency or rate of branded pharmaceutical price
appreciation or generic pharmaceutical price deflation; changes in the distribution patterns or reimbursement
rates for health-care products and/or services; the results, consequences, effects or timing of any inquiry or
investigation by any regulatory authority or any legal or administrative proceedings; future actions of regulatory
bodies or government authorities relating to Cardinal Health’s manufacturing or sale of products and other costs
or claims that could arise from its manufacturing, compounding or repackaging operations or from its other
services; difficulties, delays or additional costs in implementing the restructuring program announced on July 8,
2008; the costs, difficulties and uncertainties related to the integration of acquired businesses; and conditions in
the pharmaceutical market and general economic and market conditions. This news release reflects
management’s views as of Aug. 7, 2008. Except to the extent required by applicable law, Cardinal Health
undertakes no obligation to update or revise any forward-looking statement.
-more-